Vasculitis Risk Assessment

Vasculitis risk assessment identifies patients at elevated risk for blood vessel inflammation. Drug-induced vasculitis occurs with hydralazine and minocycline. Immunological markers predict susceptibility. Inflammatory symptom assessment guides investigation. Vasculitis confirmation requires vessel biopsy or imaging.

Clinical monitoring detects vasculitis emergence. Discontinuation of causative drugs prevents progression. Corticosteroid therapy suppresses inflammation. Regulatory submissions address vasculitis risks. Post-approval surveillance identifies vasculitis patterns.